Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ: ILMN )

134.96 -0.25 (-0.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Illumina, Inc. - Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Illumina's Interns Contribute Over 800 Hours on Social Impact Projects
SOURCE: Illumina 
Via 3BL Media
58 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares climbed 63.7% to close at $1.22 on Thursday after dropping 12% on Wednesday. Sonnet BioTherapeutics recently... 
Via Benzinga
Microsoft And Cisco Gain As The QQQ Bounces Back Thursday
U.S. indices bounced back Thursday after falling Wednesday amid macro uncertainty due to COVID-19 delta variant concerns. The Invesco QQQ Trust Series 1 (NASDAQ: QQQ) gained... 
Via Benzinga
Exposures COVID-19
Illumina slides after 'Confusing' close of Grail deal amid antitrust probe
Citi sees some risk that Illumina's tactic does not sit well with the regulatory bodies. 
Via Talk Markets
Somatic Genetic Testing Market to See Thriving Worldwide : Genomics, Illumina, Invivoscribe
Stay up-to-date with Global Somatic Genetic Testing Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Exposures COVID-19
Why Illumina Stock Just Dropped 10%
The genetic-testing company just blatantly defied its regulators. 
Via The Motley Fool
38 Stocks Moving In Thursday's Mid-Day Session
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares jumped 141% to $1.7950 after dropping 12% on Wednesday. Sonnet BioTherapeutics recently reported its financial... 
Via Benzinga
Illumina Stock Nosedives After DNA Giant Makes A 'Maverick Move' In Its Grail Takeover
Illumina stock tumbled Thursday after the company finished its $8 billion acquisition of Grail despite an ongoing investigation in Europe. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021
Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ: 
Via Benzinga
Illumina Completes Grail Buyout Despite Uncertainty In Regulatory Process
In defiance of FTC and EU scrutiny, Illumina Inc (NASDAQ: ILMN) went ahead to complete its $8 billion acquisition of Grail. The finalization of the buyout... 
Via Benzinga
Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test
SOURCE: Illumina 
Via 3BL Media
Topics Death Regulatory Compliance
Exposures COVID-19 Death Legal
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Providence Molecular Genomics Lab Utilizes Illumina Technology to Offer Genomics for All
Providence Molecular Genomics Lab Utilizes Illumina Technology to Offer Genomics for All 
Via News Direct
Topics Product Recall
Exposures Legal Product Safety
Providence Molecular Genomics Lab Utilizes Illumina Technology to Offer Genomics for All
SOURCE: Illumina 
Via 3BL Media
Topics Product Recall
Exposures Legal Product Safety
Illumina Stock Earns Membership In Elite Club
Illumina saw its IBD SmartSelect Composite Rating rise to 97 Tuesday, up from 93 the day before. 
Via Investor's Business Daily
CD Genomics Launched Viral Genome Sequencing Service to Help Scientists Fight Against Viruses
Via Get News
Illumina Coordinates Research and Efforts in China’s Rare Disease Community
Illumina Coordinates Research and Efforts in China’s Rare Disease Community 
Via News Direct
Illumina Coordinates Research and Efforts in China’s Rare Disease Community
SOURCE: Illumina 
Via 3BL Media
Illumina Delivers a Beat and a Raise in Q2
According to CEO Francis deSouza, the genetic life-sciences company is "firing on all cylinders." 
Via The Motley Fool
Topics Earnings
Exposures Financial
EU Regulators Temporarily Pause Illumina, Grail Deal Investigation
The European Commission has temporarily suspended the provisional deadline for its investigation into Illumina Inc's (NASDAQ: ILMN) plans to buy Grail Inc,... 
Via Benzinga
Extending COVID Surveillance Capabilities Beyond Big Cities
With the debut of Illumina's COVIDSeq Assay, smaller labs are participating in Covid-19 surveillance 
Via News Direct
Exposures COVID-19
Forget Robinhood, These 3 Healthcare Stocks Are Better Buys
Wait for pitches that are easy to hit before taking a swing. 
Via The Motley Fool
What Does the Future Look Like for Illumina Stock?
The leader in the genomics space is being treated like a monopoly, and is now running into federal regulation and oversight. 
Via The Motley Fool
Extending COVID Surveillance Capabilities Beyond Big Cities
SOURCE: Illumina 
Via 3BL Media
Exposures COVID-19
Illumina Donates Next-Generation Sequencing Capabilities to Support Indigenous Scientists
Next-generation sequencing is helping Native nations with sovereignty and genetic research 
Via News Direct
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Illumina Donates Next-Generation Sequencing Capabilities to Support Indigenous Scientists
SOURCE: Illumina 
Via 3BL Media
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Why Does Illumina Want to Reunite With Grail?
The genomics leader might be hitting a ceiling in its original business. 
Via The Motley Fool
Tesla And eBay Fall As The QQQ Closes Lower
U.S. indices had a mixed day of trading Friday following better-than-expected jobs data. The unemployment rate for July came in at 5.4%, which was below the 5.7%... 
Via Benzinga
Illumina Q2 Earnings Boosted By Robust Growth In Core Sequencing Business; Uplifts FY21 Outlook
lumina Inc reported after the close of the market on Thursday that its second-quarter revenues grew 78% Y/Y to $1.13 billion, beating the consensus of $1.01 billion, driven by strength in its core... 
Via Talk Markets
Illumina Stock Will Be Unstoppable Once the Grail Acquisition Gets Approved
Illumina will likely be allowed to buy Grail. But even without Grail, ILMN stock is very attractive, given its strong growth drivers. 
Via InvestorPlace
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.